Printed from Voxsanity (voxsanity.com.au) — NCT07052903 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have a confirmed diagnosis of ATTR amyloidosis affecting the heart, either the inherited form (hATTR) or the age-related form (wATTR).
People who have a history of heart failure, with at least one previous hospital stay for heart failure, or who have heart failure symptoms that require treatment with a water pill (diuretic).
People whose blood test shows a specific heart stress marker (NT-proBNP) within a certain range — between 300 and 8,500 ng/L at the screening visit, or between 600 and 8,500 ng/L for those with a permanent or persistent irregular heart rhythm called atrial fibrillation (confirm exact values with trial site).
People who are already taking an approved TTR stabiliser medication (such as tafamidis or acoramidis) or other heart failure treatments may still be considered, at the treating doctor's discretion.
Who may not be able to join:
People with the most severe level of heart failure (Class IV), or those with the second most severe level (Class III) combined with the most advanced stage of ATTR amyloidosis disease (Stage 3).
People with severe nerve damage in their legs or feet that significantly affects their ability to walk or move around, classified as PND Score IIIa, IIIb, or IV (confirm with trial site).
People whose kidneys are not working well enough, specifically those with a kidney function score (eGFR) below 30 mL/min/1.73m² at the screening visit.
People who have previously received, or are currently receiving, a therapy designed to lower TTR protein levels in the body.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Medical Director, Alnylam Pharmaceuticals
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07052903
Sponsor: Alnylam Pharmaceuticals
Phase: Phase 3
Status: Recruiting
Condition: Cardiomyopathy
Trial contact: 1-877-ALNYLAM
More information: https://clinicaltrials.gov/study/NCT07052903
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have a confirmed diagnosis of ATTR amyloidosis affecting the heart, either the inherited form (hATTR) or the age-related form (wATTR).
People who have a history of heart failure, with at least one previous hospital stay for heart failure, or who have heart failure symptoms that require treatment with a water pill (diuretic).
People whose blood test shows a specific heart stress marker (NT-proBNP) within a certain range — between 300 and 8,500 ng/L at the screening visit, or between 600 and 8,500 ng/L for those with a permanent or persistent irregular heart rhythm called atrial fibrillation (confirm exact values with trial site).
People who are already taking an approved TTR stabiliser medication (such as tafamidis or acoramidis) or other heart failure treatments may still be considered, at the treating doctor's discretion.
Who may not be able to join:
People with the most severe level of heart failure (Class IV), or those with the second most severe level (Class III) combined with the most advanced stage of ATTR amyloidosis disease (Stage 3).
People with severe nerve damage in their legs or feet that significantly affects their ability to walk or move around, classified as PND Score IIIa, IIIb, or IV (confirm with trial site).
People whose kidneys are not working well enough, specifically those with a kidney function score (eGFR) below 30 mL/min/1.73m² at the screening visit.
People who have previously received, or are currently receiving, a therapy designed to lower TTR protein levels in the body.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Alnylam Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
2 July 2025
Est. completion
28 May 2030
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇱 Chile
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
Hong Kong
🇭🇺 Hungary
🇮🇪 Ireland
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇲🇾 Malaysia
🇳🇱 Netherlands
🇳🇿 New Zealand
🇳🇴 Norway
🇵🇱 Poland
🇵🇹 Portugal
🇷🇴 Romania
🇸🇰 Slovakia
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
🇹🇼 Taiwan
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Composite outcome of all-cause mortality and recurrent cardiovascular [CV] events (CV hospitalizations and urgent heart failure [HF] visits)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.